Comparison of BQ123, Epoprostenol, and Verapamil as Vasodilators During Normothermic Ex Vivo Liver Machine Perfusion
Sign Up to like & getrecommendations! Published in 2018 at "Transplantation"
DOI: 10.1097/tp.0000000000002021
Abstract: Background The optimal vasodilator to avoid hepatic artery vasospasm during normothermic ex vivo liver perfusion (NEVLP) is yet to be determined. We compared safety and efficacy of BQ123 (endothelin1 antagonist), epoprostenol (prostacyclin analogue), and verapamil… read more here.
Keywords: bq123; epoprostenol; perfusion; group ... See more keywords
Withdrawal of long-term epoprostenol therapy in pulmonary arterial hypertension (PAH)
Sign Up to like & getrecommendations! Published in 2017 at "Pulmonary Circulation"
DOI: 10.1177/2045893217702401
Abstract: Once initiated for pulmonary arterial hypertension (PAH), epoprostenol treatment usually needs to be delivered for an indefinite duration. It is possible that some participants could be transitioned from epoprostenol to oral therapies. We retrospectively evaluated… read more here.
Keywords: epoprostenol; transition; group; withdrawal ... See more keywords
Transition from intravenous epoprostenol to selexipag in pulmonary arterial hypertension: a word of caution
Sign Up to like & getrecommendations! Published in 2020 at "European Respiratory Journal"
DOI: 10.1183/13993003.02418-2019
Abstract: Prostacyclin analogues targeting the prostacyclin pathway are used to treat patients with pulmonary arterial hypertension (PAH), and are given either by an intravenous, subcutaneous or inhaled route [1]. Continuous i.v. infusion of epoprostenol has received… read more here.
Keywords: pulmonary arterial; transition intravenous; epoprostenol; arterial hypertension ... See more keywords